Target intelligence / Profile preview

Accessory gene regulator protein C (AgrC) (AgrC)

Target
AgrC
Molecular classification
Histidine kinase, Two-component system sensor, Receptor, Enzyme
01

Overview

Accessory gene regulator protein C (AgrC) is a transmembrane histidine kinase that serves as the sensor component of the accessory gene regulator (agr) quorum-sensing system, primarily in Staphylococcus aureus (UniProt P0C1P6). It is activated by the binding of secreted autoinducing peptides (AIPs), which triggers a phosphorylation cascade leading to the activation of the response regulator AgrA (PubMed: 10493711). This system acts as a master switch, controlling the transition from a colonizing phenotype to an invasive, virulent phenotype by upregulating toxins and downregulating surface adhesins (PubMed: 23403495). As a therapeutic target, AgrC is highly attractive for anti-virulence therapy, which aims to disarm the pathogen without exerting the strong selective pressure for resistance seen with traditional biocidal antibiotics (PubMed: 24413152). Inhibitors of AgrC, such as synthetic AIP analogs or natural products like Solonamide B, can attenuate the production of virulence factors like alpha-hemolysin and proteases, potentially improving patient outcomes in severe staphylococcal infections (PubMed: 24413152).

Other names
Histidine kinase AgrCQuorum-sensing sensor kinase AgrCAgrC receptorStaphylococcal accessory gene regulator C
02

Mechanism of action

Inhibition of the binding of autoinducing peptides (AIPs) to the AgrC receptor, preventing autophosphorylation and subsequent activation of the AgrA response regulator, thereby suppressing the expression of virulence factors (PubMed: 23403495, PubMed: 24413152).

03

Biological functions

Quorum sensingSignal transductionRegulation of virulence factorsBiofilm formationBacterial communication
04

Disease associations

InfectionStaphylococcus aureus infectionMethicillin-resistant Staphylococcus aureus (MRSA) infectionSepsisSkin and soft tissue infectionEndocarditis
05

Safety considerations

Potential for cross-reactivity with commensal staphylococci (PubMed: 23403495)Incomplete suppression of virulence leading to persistent infectionDevelopment of resistance through mutations in the agr locusBioavailability and stability of peptide-based inhibitorsPotential for agr-null mutants to exhibit increased biofilm formation in certain contexts
06

Interacting drugs

Autoinducing peptide (AIP) analogs

7 more in the full profile.

07

Biomarkers

RNAIII expression levels (PubMed: 23403495)Alpha-hemolysin (Hla) production (PubMed: 24413152)Extracellular protease activityAutoinducing peptide (AIP) concentration

Beyond the preview

Go deeper on Accessory gene regulator protein C (AgrC) (AgrC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accessory gene regulator protein C (AgrC) (AgrC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call